Holen Sie sich die Stockscreener-App
52.91
0.55%
-0.29
Schlusskurs vom Vortag:
$53.20
Offen:
$54.09
24-Stunden-Volumen:
1.93M
Relative Volume:
1.67
Marktkapitalisierung:
$5.11B
Einnahmen:
$7.50M
Nettoeinkommen (Verlust:
$-383.17M
KGV:
-11.25
EPS:
-4.7048
Netto-Cashflow:
$-307.84M
1W Leistung:
+1.38%
1M Leistung:
-1.49%
6M Leistung:
+22.39%
1J Leistung:
+65.86%
1-Tages-Spanne:
$52.53
$54.73
1-Wochen-Bereich:
$51.54
$54.73
52-Wochen-Spanne:
$30.00
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
52.91 | 5.11B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Precision Trading with Xenon Pharmaceuticals Inc. (XENE) Risk Zones - Stock Traders Daily
Xenon Pharmaceuticals Inc (XENE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenon Pharmaceuticals Inc (XENE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenon Pharmaceuticals Inc (XENE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xenon Pharmaceuticals StockAnalyst consensus and outlook mid-2026 - AD HOC NEWS
Xenon Pharmaceuticals Inc (XENE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xenon Pharmaceuticals Inc (XENE) Institutional Confidence - TradingKey
Xenon Pharmaceuticals Inc (XENE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xenon Pharmaceuticals Inc (XENE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xenon Pharmaceuticals Inc (XENE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate - Yahoo Finance
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan - Stock Titan
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade - Stock Titan
[144] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
Xenon Pharmaceuticals (XENE) director receives new RSUs, options and RSU vesting - Stock Titan
Xenon Pharmaceuticals (XENE) director awarded RSUs, options and exercises vested RSUs - Stock Titan
Xenon Pharmaceuticals (XENE) director receives RSUs, options and nets vested shares - Stock Titan
Xenon Pharmaceuticals (XENE) investors approve 2026 equity plan and pay votes - Stock Titan
Xenon Pharmaceuticals (XENE) director exercises RSUs and gets new option award - Stock Titan
Xenon Q1 earnings match estimates, pipeline development in focus - MSN
Xenon Pharmaceuticals Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Xenon Pharmaceuticals Inc. Rings the Opening Bell - Nasdaq
Wells Fargo Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Recent Pullback And Strong Multi Year Returns - Sahm
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
XENE Q1 2026 Earnings: EPS Beat Amid Continued Clinical Development FocusOne-Time Gain Impact - newsline.com
J.P. Morgan Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $82 - Moomoo
XENE Maintains Overweight Rating -- Price Target Raised to $82.0 - GuruFocus
Xenon Pharmaceuticals (XENE) Edges Higher Amidst Neutral TradingFactor ETF Flow - thelegaladvocate.com
Trading the Move, Not the Narrative: (XENE) Edition - Stock Traders Daily
Xenon Pharmaceuticals (XENE) Holds Near Support Amid Modest PullbackVolatility Skew - thelegaladvocate.com
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE) - Insider Monkey
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
5 Best Performing Canadian Stocks So Far in 2026 - Insider Monkey
A Look At Xenon Pharmaceuticals (XENE) Valuation After Strong Long Term Returns And Recent Momentum Cooldown - Sahm
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing - AOL.com
Which Is a Better Investment, Sarepta Therapeutics, Inc. or Xenon Pharmaceuticals Inc. Stock? - AAII
Xenon Pharmaceuticals stock (CA98420N1050): epilepsy data and capital raise put biotech in focus - AD HOC NEWS
DNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Janus Henderson reports 4.5% stake in Xenon Pharmaceuticals (XENE) filing - Stock Titan
Xenon Pharmaceuticals (NASDAQ: XENE) shows 5.78M-share holding, 6.26% - Stock Titan
Driehaus files Schedule 13G/A disclosing 4.87% in Xenon (XENE) - Stock Titan
XENE: Azetukalner’s strong efficacy and novel mechanism set the stage for a major epilepsy market launch - TradingView
Xenon Pharmaceuticals stock (CA98420N1050): Director exercises options for 3,500 shares - AD HOC NEWS
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):